Product Description
A drug used with another drug to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Iodine I 131-tositumomab is a form of the monoclonal antibody tositumomab that is linked to the radioactive substance iodine I 131. It is a type of radioimmunoconjugate. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/iodine-i-131-tositumomab)
Mechanisms of Action: CD20 Binder,Radioactive Agent
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Follicular Lymphoma|Lymphoma, Non-Hodgkin
Phase 2: Lymphoma, Non-Hodgkin|Follicular Lymphoma|Multiple Myeloma|Lymphoma|Plasmablastic Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Waldenstrom Macroglobulinemia|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Large-Cell Anaplastic Lymphoma|Diffuse Large B-Cell Lymphoma|Leukemia, Plasma Cell|Hodgkin Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|B-Cell Leukemia|Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma
Phase 1: Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Diffuse Large B-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Follicular Lymphoma|Waldenstrom Macroglobulinemia|B-Cell Marginal Zone Lymphoma|Plasmablastic Lymphoma|Burkitt Lymphoma|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CCBX001-053 | P3 |
Withdrawn |
Lymphoma, Non-Hodgkin|Follicular Lymphoma |
2021-02-01 |
|
| CDR0000615104 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Follicular Lymphoma |
2017-04-01 |
|
| UPCC 18406 | P1 |
Completed |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2015-05-01 |
|
| PSOC 2301 | P2 |
Completed |
Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2015-02-01 |